137 related articles for article (PubMed ID: 37805073)
21. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle.
Pacak CA; Suzuki-Hatano S; Khadir F; Daugherty AL; Sriramvenugopal M; Gosiker BJ; Kang PB; Cade WT
J Transl Med; 2023 Oct; 21(1):748. PubMed ID: 37875924
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution and Tolerability of AAV-PHP.B-CBh-
Palazzi X; Pardo ID; Sirivelu MP; Newman L; Kumpf SW; Qian J; Franks T; Lopes S; Liu J; Monarski L; Casinghino S; Ritenour C; Ritenour H; Dubois C; Olson J; Graves J; Alexander KE; Coskran T; Lanz TA; Brady J; McCarty D; Suryanarayan S; Whiteley LO
Hum Gene Ther; 2022 Feb; 33(3-4):175-187. PubMed ID: 34931542
[TBL] [Abstract][Full Text] [Related]
23. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
Li Z; Li Y; Chang HP; Yu X; Shah DK
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
[TBL] [Abstract][Full Text] [Related]
24. Induction of Immune Tolerance to Foreign Protein via Adeno-Associated Viral Vector Gene Transfer in Mid-Gestation Fetal Sheep.
Davey MG; Riley JS; Andrews A; Tyminski A; Limberis M; Pogoriler JE; Partridge E; Olive A; Hedrick HL; Flake AW; Peranteau WH
PLoS One; 2017; 12(1):e0171132. PubMed ID: 28141818
[TBL] [Abstract][Full Text] [Related]
25. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
26. Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9.
Chai Z; Zhang X; Dobbins AL; Rigsbee KM; Wang B; Samulski RJ; Li C
Hum Gene Ther; 2019 Jul; 30(7):829-840. PubMed ID: 30700148
[TBL] [Abstract][Full Text] [Related]
27. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
28. JSRV Intragenic Enhancer Element Increases Expression from a Heterologous Promoter and Promotes High Level AAV-mediated Transgene Expression in the Lung and Liver of Mice.
Yu DL; Chow N; Wootton SK
Viruses; 2020 Nov; 12(11):. PubMed ID: 33172105
[TBL] [Abstract][Full Text] [Related]
29. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.
Shah DK; Betts AM
MAbs; 2013; 5(2):297-305. PubMed ID: 23406896
[TBL] [Abstract][Full Text] [Related]
30. Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.
Hammond SL; Leek AN; Richman EH; Tjalkens RB
PLoS One; 2017; 12(12):e0188830. PubMed ID: 29244806
[TBL] [Abstract][Full Text] [Related]
31. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
Ayyar VS; Jusko WJ
Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
[TBL] [Abstract][Full Text] [Related]
32. Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration.
Chai Z; Zhang X; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2018 Sep; 286():415-424. PubMed ID: 30107215
[TBL] [Abstract][Full Text] [Related]
33. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
34. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343
[TBL] [Abstract][Full Text] [Related]
35. Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery.
Talkington AM; Wessler T; Lai SK; Cao Y; Forest MG
Bull Math Biol; 2021 Nov; 83(12):123. PubMed ID: 34751832
[TBL] [Abstract][Full Text] [Related]
36. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo.
Ren C; Kumar S; Shaw DR; Ponnazhagan S
Hum Gene Ther; 2005 Sep; 16(9):1047-57. PubMed ID: 16149903
[TBL] [Abstract][Full Text] [Related]
37. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.
Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM
Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.
Chai Z; Zhang X; Dobbins AL; Frost EA; Samulski RJ; Li C
Viruses; 2019 Dec; 11(12):. PubMed ID: 31835440
[TBL] [Abstract][Full Text] [Related]
39. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
[TBL] [Abstract][Full Text] [Related]
40. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
